1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

Anthony J. Olszanski, Jason J. Luke, Patricia LoRusso, Gerald S. Falchook, Philippe L. Bédard, Rachel E. Sanborn, Sandip Pravin Patel, Donald P. Orr, John P. Gibbs, Chun Li, Y-C. Huang, R. Gregory, S. Perera, Ruizhe Xu, Aniket Joshi, Min Young Lee, Jeffrey J. Raizer, Xīn Gào